RBC Capital lowered the firm’s price target on Intellia Therapeutics to $54 from $60 and keeps an Outperform rating on the shares. Overall the firm remain buyers given it view Intellia as “best positioned for in vivo gene editing, which the firm calls “the better approach vs ex vivo. Fundamentally, the firm believes Intellia has “two drugs in two multi-billion dollar markets,” adding that it is updating its price target to reflect the quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- NTLA Upcoming Earnings Report: What to Expect?
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
- Intellia receives authorization to initiate Phase 1/2 trial of NTLA-3001
- Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
Questions or Comments about the article? Write to editor@tipranks.com